

G1 O,S,N

G2 CH2,CH,A,Ak

G3 C,N

Structure attributes must be viewed using STN Express query preparation.

```
=> s l1
SAMPLE SEARCH INITIATED 08:59:54 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -    19603 TO ITERATE

 10.2% PROCESSED     2000 ITERATIONS                                0 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:       383678 TO   400442
PROJECTED ANSWERS:               0 TO        0

L2             0 SEA SSS SAM L1

=> s l1 sss full
FULL SEARCH INITIATED 09:00:02 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -   393288 TO ITERATE

100.0% PROCESSED   393288 ITERATIONS                               33 ANSWERS
SEARCH TIME: 00.00.10

L3            33 SEA SSS FUL L1

=> file caplus
COST IN U.S. DOLLARS                          SINCE FILE      TOTAL
                                                   ENTRY    SESSION
FULL ESTIMATED COST                               166.94     167.15

FILE 'CAPLUS' ENTERED AT 09:00:15 ON 19 OCT 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)
```

FILE COVERS 1907 - 19 Oct 2006 VOL 145 ISS 17
FILE LAST UPDATED: 17 Oct 2006 (20061017/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

http://www.cas.org/infopolicy.html

=> s l3
L4 7 L3

=> d ibib abs hitstr tot

L4 ANSWER 1 OF 7 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2001:247321 CAPLUS
DOCUMENT NUMBER: 134:280852
TITLE: Quinazolinones useful as glycoprotein IbIX antagonists, and their preparation and use for control of thrombotic disorders
INVENTOR(S): Mederski, Werner; Devant, Ralf; Barnickel, Gerhard; Bernotat-danielowski, Sabine; Melzer, Guido; Dhanoa, Daljit; Zhao, Bao-ping; Rinker, James; Player, Mark; Soll, Richard
PATENT ASSIGNEE(S): Merck Patent Gmbh, Germany; et al.
SOURCE: PCT Int. Appl., 104 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001023365	A1	20010405	WO 2000-EP8940	20000913
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2385921	AA	20010405	CA 2000-2385921	20000913
BR 2000014294	A	20020521	BR 2000-14294	20000913
EP 1216235	A1	20020626	EP 2000-965991	20000913
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
US 6890930	B1	20050510	US 2002-89166	20000913
NO 2002001502	A	20020326	NO 2002-1502	20020326
PRIORITY APPLN. INFO.:			US 1999-407958 A	19990928
			US 1999-287586P P	19990928
			WO 2000-EP8940 W	20000913

OTHER SOURCE(S): MARPAT 134:280852
GI

L4 ANSWER 1 OF 7 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



I



II

AB Quinazolinones I and their pharmaceutically tolerable salts and solvates are disclosed [in which R, R1 = H, A, OH, OA, OCH2Ar, Hal, NH2, NHA, NA2, NO2, cyano, COR2, CONH2, CONHA, CONA2, CO2H, CO2A, SO2A; R2, R3 = H, A, C(:NH)NH2, solid phase; R4 = Ar, phenylalkyl, cycloalkyl, Het; Y = bond, C2-4 alkylene; Z = bond, phenylene; A = (un)branched C1-6 alkyl; Ar = (un)substituted Ph, naphthyl, biphenyl, or benzofuranyl; Het = (un)substituted, (un)saturated mono- or bicyclic NOS heterocyclyl; Hal = F, Cl, Br, or iodo; n = 1-3; m = 0-3; with a variety of provisos]. The compds. are glycoprotein IbIX antagonists (no data), useful for treatment or prophylaxis of a variety of thrombotic disorders, or as anti-adhesive substances for implants, catheters, or heart pacemakers. For instance, an exemplary amine, 3-(aminomethyl)benzylamine, was supported on p-nitrophenyl carbonate resin, then coupled with various Fmoc-protected anthranilic acids. Cleavage of the Fmoc group, cyclocondensation with various aldehydes R4YCHO, oxidation of the resultant dihydroquinazolinone ring system, and cleavage from the resin with CF3CO2H, gave a variety of compds. I, e.g., the preferred compound II.
IT 332363-12-9P, 3-(3-Aminomethylbenzyl)-2-[2-(4-dimethylaminophenyl)vinyl]-6-chloro-3H-quinazolin-4-one 332363-13-0P, 3-(3-Aminomethylbenzyl)-2-[2-(4-dimethylaminophenyl)vinyl]-7-chloro-3H-quinazolin-4-one
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate)
RN 332363-12-9 CAPLUS
CN 4(3H)-Quinazolinone, 3-[[3-(aminomethyl)phenyl]methyl]-6-chloro-2-[2-[4-(dimethylamino)phenyl]ethenyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 1 OF 7 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 332363-13-0 CAPLUS
CN 4(3H)-Quinazolinone, 3-[[3-(aminomethyl)phenyl]methyl]-7-chloro-2-[2-[4-(dimethylamino)phenyl]ethenyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2001:247320 CAPLUS
DOCUMENT NUMBER: 134:280851
TITLE: Quinazolinones useful as glycoprotein IbIX antagonists, and their preparation and use for control of thrombotic disorders
INVENTOR(S): Mederski, Werner; Devant, Ralf; Barnickel, Gerhard; Bernotat-danielowski, Sabine; Melzer, Guido; Dhanoa, Daljit; Zhao, Bao-ping; Rinker, James; Player, Mark; Soll, Richard
PATENT ASSIGNEE(S): Merck Patent Gmbh, Germany; et al.
SOURCE: PCT Int. Appl., 64 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001023364	A1	20010405	WO 2000-EP8939	20000913
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2385918	AA	20010405	CA 2000-2385918	20000913
BR 2000014311	A	20020521	BR 2000-14311	20000913
EP 1216233	A1	20020626	EP 2000-962482	20000913
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
NO 2002001503	A	20020326	NO 2002-1503	20020326
US 7060706	B1	20060613	US 2002-89167	20020829
PRIORITY APPLN. INFO.:			US 1999-407939 A	19990928
			US 1999-325777P P	19990928
			WO 2000-EP8939 W	20000913

OTHER SOURCE(S): MARPAT 134:280851
GI

L4 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



I



II

AB Quinazolinones I and their pharmaceutically tolerable salts and solvates are disclosed [in which R, R1 = H, A, OH, OA, OCH2Ar, Hal, NH2, NHA, NA2, NO2, cyano, COR2, CONH2, CONHA, CONA2, CO2H, CO2A, SO2A; R2, R3 = H, A, C(:NH)NH2, solid phase; R4 = Ar, phenylalkyl, cycloalkyl, Het; Y = bond, C2-4 alkylene; A = (un)branched C1-6 alkyl; Ar = (un)substituted Ph, naphthyl, biphenyl, or benzofuranyl; Het = (un)substituted, (un)saturated mono- or bicyclic NOS heterocyclyl; Hal = F, Cl, Br, or iodo; n, m = 0-3].

The compds. are glycoprotein IbIX antagonists (no data), useful for treatment or prophylaxis of a variety of thrombotic disorders, or as anti-adhesive substances for implants, catheters, or heart pacemakers. For instance, an exemplary amine, [[3-(aminomethyl)cyclohexyl]methyl]amine, was supported on p-nitrophenyl carbonate resin, then coupled with various Fmoc-protected anthranilic acids. Cleavage of the Fmoc group, cyclocondensation with various aldehydes R4YCHO, oxidation of the resultant dihydroquinazolinone ring system, and cleavage from the resin with CF3CO2H, gave a variety of compds. I, e.g., the preferred compound II.

IT 332121-76-3P, 3-[[3-(Aminomethyl)cyclohexyl]methyl]-2-[2-(4-dimethylaminophenyl)vinyl]-6-chloro-3H-quinazolin-4-one
332121-77-4P, 3-[[3-(Aminomethyl)cyclohexyl]methyl]-2-[2-(4-dimethylaminophenyl)vinyl]-6-methyl-3H-quinazolin-4-one
332121-78-5P, 3-[[3-(Aminomethyl)cyclohexyl]methyl]-2-[2-(4-dimethylaminophenyl)vinyl]-7-chloro-3H-quinazolin-4-one
332121-79-6P, 3-[[3-(Aminomethyl)cyclohexyl]methyl]-2-[2-(4-dimethylaminophenyl)vinyl]-6-methoxy-3H-quinazolin-4-one
332121-80-9P, 3-[[3-(Aminomethyl)cyclohexyl]methyl]-2-[2-(4-dimethylaminophenyl)vinyl]-3H-quinazolin-4-one
RL: BAC (Biological activity or effector, except adverse); BSU (Biological

L4 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)





RN 332121-79-6 CAPLUS
CN 4(3H)-Quinazolinone, 3-[[3-(aminomethyl)cyclohexyl]methyl]-2-[2-[4-(dimethylamino)phenyl]ethenyl]-6-methoxy- (9CI) (CA INDEX NAME)





RN 332121-80-9 CAPLUS
CN 4(3H)-Quinazolinone, 3-[[3-(aminomethyl)cyclohexyl]methyl]-2-[2-[4-(dimethylamino)phenyl]ethenyl]- (9CI) (CA INDEX NAME)





REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; prepn. of quinazolinone deriva. as glycoprotein IbIX antagonists)

RN 332121-76-3 CAPLUS
CN 4(3H)-Quinazolinone, 3-[[3-(aminomethyl)cyclohexyl]methyl]-6-chloro-2-[2-[4-(dimethylamino)phenyl]ethenyl]- (9CI) (CA INDEX NAME)





RN 332121-77-4 CAPLUS
CN 4(3H)-Quinazolinone, 3-[[3-(aminomethyl)cyclohexyl]methyl]-2-[2-[4-(dimethylamino)phenyl]ethenyl]-6-methyl- (9CI) (CA INDEX NAME)





RN 332121-78-5 CAPLUS
CN 4(3H)-Quinazolinone, 3-[[3-(aminomethyl)cyclohexyl]methyl]-7-chloro-2-[2-[4-(dimethylamino)phenyl]ethenyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 3 OF 7 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1996:12269 CAPLUS
DOCUMENT NUMBER: 124:175225
TITLE: Electron impact-promoted fragmentation of some substituted 4-quinazolones
AUTHOR(S): Badr, M. Z. A.; Hammerum, Steen; Duffield, A. M.
CORPORATE SOURCE: Chemistry Department, Assiut Univ., Assiut, Egypt
SOURCE: Journal of Mass Spectrometry (1995), 30(12), 1701-6
CODEN: JMSPPJ; ISSN: 1076-5174
PUBLISHER: Wiley
DOCUMENT TYPE: Journal
LANGUAGE: English

AB Low-resolution mass spectra, and where appropriate complete high-resolution spectra, were recorded for 29 2,3-disubstituted 4-quinazolones. Rationalizations are presented for the principal fragmentation modes of this series of aromatic compds. Four of the 4-quinazolones which contain a vinyl-2-furanyl group attached to C-2 of the heterocyclic ring exhibited an unusual loss of C3H2O from their resp. mol. ions.

IT 56479-05-1
RL: PEP (Physical, engineering or chemical process); PRP (Properties); RCT (Reactant); PROC (Process); RACT (Reactant or reagent)
(electron impact-promoted fragmentation of substituted 4-quinazolones)

RN 56479-05-1 CAPLUS
CN 4(3H)-Quinazolinone, 2-[2-(4-nitrophenyl)ethenyl]-3-(phenylmethyl)-, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



L4 ANSWER 4 OF 7 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1983:143365 CAPLUS
DOCUMENT NUMBER: 98:143365
TITLE: Synthesis and antiparkinsonian activity of styryl quinazolones
AUTHOR(S): Kumar, Pradeep; Nath, C.; Bhargava, K. P.; Shanker, K.
CORPORATE SOURCE: Dep. Pharmacol. Therapeut., King George's Med. Coll., Lucknow, 226003, India
SOURCE: Pharmazie (1982), 37(11), 802
CODEN: PHARAT; ISSN: 0031-7144
DOCUMENT TYPE: Journal
LANGUAGE: English
GI



I II



III

AB Condensation of acetanthranils I (R = H, Br, iodo; R1 = H, Br) with R2C6H4NHNH2 (R2 = H, 2-Me, 4-NO2) gave methylquinazolines II, which condensed with benzaldehydes to give styrylquinazolines III (R3 = 4-MeO, 4-NO2, Me2N, 3-NO2, 2-Cl, 2-F, R4 = H; R3 = 3-Me, R4 = 4-HO; R3R4 = CH2O2). Antiparkinsonian activities of III at 100 mg/kg in rats were tested against oxotremorine induced tremors and reserpine induced rigidity. III (R = R1 = R2 = R3 = H, R4 = 4-MeO; R = Br, R1 = R2 = R3 = H, R4 = 2-Cl) possessed maximum activity with a tremor index of 2.4 (control 3.0) and 20% rigidity (control 100%).

IT 85226-44-4P 85226-45-5P 85226-47-7P 85226-48-8P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation and antiparkinsonian activity of)

RN 85226-44-4 CAPLUS
CN 4(3H)-Quinazolinone, 2-[2-[4-(dimethylamino)phenyl]ethenyl]-3-(phenylamino)- (9CI) (CA INDEX NAME)

L4 ANSWER 4 OF 7 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 85226-45-5 CAPLUS
CN 4(3H)-Quinazolinone, 2-[2-[4-(dimethylamino)phenyl]ethenyl]-3-[(4-nitrophenyl)amino]- (9CI) (CA INDEX NAME)



RN 85226-47-7 CAPLUS
CN 4(3H)-Quinazolinone, 2-[2-[4-(dimethylamino)phenyl]ethenyl]-6-iodo-3-[(4-nitrophenyl)amino]- (9CI) (CA INDEX NAME)



RN 85226-48-8 CAPLUS
CN 4(3H)-Quinazolinone, 6-iodo-3-[(2-methylphenyl)amino]-2-[2-(3-nitrophenyl)ethenyl]- (9CI) (CA INDEX NAME)



L4 ANSWER 4 OF 7 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

L4 ANSWER 5 OF 7 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1979:611313 CAPLUS
DOCUMENT NUMBER: 91:211313
TITLE: Studies on the synthesis of 2,3-disubstituted 4(3H)quinazolinone
AUTHOR(S): Badr, M. Z. A.; El-Sherif, H. A. H.
CORPORATE SOURCE: Fac. Sci., Univ. Assiut, Assiut, Egypt
SOURCE: Egyptian Journal of Chemistry (1978), Volume Date 1976, 19(2), 341-6
CODEN: EGJCA3; ISSN: 0367-0422
DOCUMENT TYPE: Journal
LANGUAGE: English
GI



I II

AB Quinazolinone derivs. (I; R = Et, Ph, PhCH2; R1 = aryl, 2-furyl) were prepared in 80-90% yields by Knoevenagel condensation of II with R1CHO in absolute EtOH containing EtONa.

IT 56479-05-1P 71822-48-5P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 56479-05-1 CAPLUS
CN 4(3H)-Quinazolinone, 2-[2-(4-nitrophenyl)ethenyl]-3-(phenylmethyl)-, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 71822-48-5 CAPLUS
CN 4(3H)-Quinazolinone, 2-[2-(3-nitrophenyl)ethenyl]-3-(phenylmethyl)-, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

L4 ANSWER 5 OF 7 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



L4 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1975:497193 CAPLUS
DOCUMENT NUMBER: 83:97193
TITLE: Synthesis of some benzoxazin-4-ones, quinazolin-4-ones, and the related products
AUTHOR(S): Messiha, N. N.; Abdel-Kader, A. M. M.; Nosseir, M. H.
CORPORATE SOURCE: Lab. Polym. Pigm., Natl. Res. Cent., Cairo, Egypt
SOURCE: Indian Journal of Chemistry (1975), 13(4), 326-8
CODEN: IJOCAP; ISSN: 0019-5103
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 83:97193
GI For diagram(s), see printed CA Issue.
AB Benzoxazinones I [R = 2-furyl, p-Me2NC6H4, 3,4-(MeO)(HO)C6H3] prepared by condensation of 2-methyl-3,1-benzoxazin-4-one with RCHO, were cleaned with R1NH2 to give o-R1NHCOC6H4NHCOCH:CHR (II, R1 = Me, Et, Bu, PhCH2, NH2; R1 = same as above). Styrylquinazolinones III were prepared by condensation of 2-methyl-3-alkylquinazolin-4-ones with RCHO. III prepared were [R = 3,4-(MeO)(HO)C6H3, R1 = Me, Et; R = 2-furyl, R1 = Me, PhCH2]. Treatment of I with NaN gave tetrazoles IV [R = 2-furyl, p-tolyl, 3,4-(MeO)(HO)C6H3] and benzimidazoles V (R = same as above, p-Me2NC6H4). II treated with NaNO2 gave (o-RCH:CHCONHC6H4NH)2CO [R = p-tolyl, 3,4-(MeO)(HO)C6H3]. Infrared studies indicated trans-olefin in these products. Uv showed that substituents caused a bathochromic shift increasing in the order p-Me<p-Cl<p-MeO<3,4-(MeO)(HO)<p-Me2N.
IT 56479-05-1 56479-06-2
RL: RCT (Reactant); RACT (Reactant or reagent)
(spectral characteristics of)
RN 56479-05-1 CAPLUS
CN 4(3H)-Quinazolinone, 2-[2-(4-nitrophenyl)ethenyl]-3-(phenylmethyl)-, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 56479-06-2 CAPLUS
CN 4(3H)-Quinazolinone, 2-[2-(2-nitrophenyl)ethenyl]-3-(phenylmethyl)-, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

L4 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



L4 ANSWER 7 OF 7 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1974:3464 CAPLUS
DOCUMENT NUMBER: 80:3464
TITLE: Action of Grignard reagents and aryllithium on 3-alkyl-2-styrylquinazol-in-4-ones and 2-styryl-3,1-benzoxazin-4-ones
AUTHOR(S): Messiha, N. N.; Doss, N. L.; Nosseir, M. H.
CORPORATE SOURCE: Lab. Polym. Pigm., Natl. Res. Cent., Cairo, Egypt
SOURCE: Indian Journal of Chemistry (1973), 11(8), 738-40
CODEN: IJOCAP; ISSN: 0019-5103
DOCUMENT TYPE: Journal
LANGUAGE: English
GI For diagram(s), see printed CA Issue.
AB Some derivs. of 2-styryl-3,1-benzoxazin-4-ones (I) and 3-alkyl-2-styrylquinazolin-4-ones (II) were prepared by reaction of the corresponding aldehyde with the ketone. 3-Alkyl- and 3-amino-2-styrylquinazol-4-ones react sep. with arylmagnesium halides (3 mole equivalent) to give 3-alkyl- and 3-amino-2-(α,α'-diarylethyl)quinazolin-4-ones, resp. With aryllithium, I and II gave o-(cinnamoylamidophenyl)diarylcarbinols and 3-alkyl-4,4'-diaryl-2-styrylquinazolines, resp. Structures were assigned on the basis of anal. ir, and uv spectral data.
IT 50830-12-1P 50830-16-5P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 50830-12-1 CAPLUS
CN 4(3H)-Quinazolinone, 2-[2-(4-nitrophenyl)ethenyl]-3-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 50830-16-5 CAPLUS
CN 4(3H)-Quinazolinone, 2-[2-(2-nitrophenyl)ethenyl]-3-(phenylmethyl)- (9CI) (CA INDEX NAME)